Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial - The Lancet Oncology
The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) | Molecular Cancer | Full Text
Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial - Journal of Thoracic Oncology
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer - Lung Cancer
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial - The Lancet
Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC) — ALK POSITIVE
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models | Nature Communications
Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer | NEJM
Crizotinib produces improved OS and PFS in EML4-ALK lung cancer... | Download Scientific Diagram
Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data | Future Oncology
Virtual clinical trial gives entrectinib edge over crizotinib against ROS1+ non-small cell lung cancer
Crizotinib - Wikipedia
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
Ensartinib
Timeline for crizotinib development. Abbreviations: ALK1, ALK-positive;... | Download Scientific Diagram
Phase III trial of crizotinib versus chemotherapy in previously treated... | Download Scientific Diagram
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer | NEJM
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression | BMC Cancer | Full Text
Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive advanced NSCLC | ESMO
Alectinib Replaces Crizotinib Drug as Potential Therapy for Advanced Lung Cancer
Ensartinib Tops Crizotinib in ALK-Positive NSCLC | MedPage Today
Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls - ScienceDirect
First-Line ALK+ mNSCLC Clinical Trial - ALECENSA® (alectinib)
